One-Offs Boost Japan's Top Firms In Mixed Q1
Pandemic Impact Limited
Executive Summary
Japan's top pharma firms benefited in several cases from one-off factors in what was a generally positive fiscal first quarter, but most full-year guidance remains unchanged for now.